Progress of SGLT2 inhibitors in the treatment of common immune-related nephropathies

被引：0

作者：

Hu, Guoqian ^{[1
]}

Wu, Yifan ^{[1
]}

Chen, Feng ^{[2
]}

Tang, Jin ^{[1
]}

机构：

[1] Cent South Univ, Xiangya Hosp 3, Dept Urol, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China

[2] Cent South Univ, Xiangya Hosp 3, Dept Nephrol, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China

来源：

INTERNATIONAL UROLOGY AND NEPHROLOGY | 2024年 / 56卷 / 12期

关键词：

SGLT2; inhibitors; Immune-related nephropathy; Chronic kidney disease; CHRONIC KIDNEY-DISEASE; ADVERSE OUTCOMES; DAPAGLIFLOZIN; PREVENTION; EFFICACY; SAFETY;

D O I：

10.1007/s11255-024-04141-2

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The immune system can lead to a variety of renal diseases through direct or indirect mechanisms. In immune-mediated nephropathy, though standardized treatment, there are still a small number of patients with further decline in renal function, which may even progress to renal failure; sodium-glucose cotransporter protein 2 (SLC5A2,SGLT2) inhibitors not only can significantly reduce blood glucose, but also have an additional protective effect on the kidneys and the heart; this review concludes the potential mechanism of the renal protective effect of SGLT2i and the new advances in the recent years in common immune-mediated nephropathies, which can provide new theoretical references to optimize the therapeutic strategy of common immune-mediated nephropathies.

引用

页码：3807 / 3813

页数：7

共 50 条

[1] Research Progress of SGLT2 Inhibitors in Cancer Treatment
Miao, Xiaoyong
Zhang, Jianing
Huang, Weiyan
Wang, Yifei
Jin, Aixia
Cao, Jianping
Zhao, Zhenzhen
DRUG DESIGN DEVELOPMENT AND THERAPY, 2025, 19 : 505 - 514
[2] SGLT2 INHIBITORS
Brito, M.
CLINICAL THERAPEUTICS, 2015, 37 (08) : E162 - E162
[3] SGLT2 inhibitors
Dardi, I.
Kouvatsos, T.
Jabbour, S. A.
BIOCHEMICAL PHARMACOLOGY, 2016, 101 : 27 - 39
[4] Are the antidiabetic SGLT2 inhibitors a cardiovascular treatment?
Vargas Delgado, Ariana P.
Requena Ibanez, Juan Antonio
Santos-Gallego, Carlos G.
Jose Badimon, Juan
CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2021, 33 (01): : 33 - 40
[5] SGLT2 inhibitors
Steyn, Lynda
SA PHARMACEUTICAL JOURNAL, 2018, 85 (01) : 72 - 75
[6] SGLT2 inhibitors in the treatment of type 2 diabetes
Hasan, Farhad M.
Alsahli, Mazen
Gerich, John E.
DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 104 (03) : 297 - 322
[7] Extrarenal Benefits of SGLT2 Inhibitors in the Treatment of Cardiomyopathies
Yerra, Veera Ganesh
Connelly, Kim A.
PHYSIOLOGY, 2024, 39 (06) : 412 - 434
[8] SGLT2 inhibitors for treatment of chronic kidney disease
Davis, S.
SA PHARMACEUTICAL JOURNAL, 2024, 91 (02) : 26 - 28
[9] SGLT2 inhibitors - a potential treatment for Alport syndrome
Mabillard, Holly
Sayer, John A.
CLINICAL SCIENCE, 2020, 134 (04) : 379 - 388
[10] SGLT2 inhibitors and the changing landscape for treatment of diabetes
Liu, Shuangbo
Lam, Anna
Wazir, Arslan
Cheema, Asim N.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2019, 15 : 861 - 867

← 1 2 3 4 5 →